Last reviewed · How we verify

tenofovir + abacavir + lopinavir/ritonavir

Hospital Clinic of Barcelona · FDA-approved active Small molecule

tenofovir + abacavir + lopinavir/ritonavir is a Antiretroviral combination therapy (NRTI + PI/boosted) Small molecule drug developed by Hospital Clinic of Barcelona. It is currently FDA-approved for HIV-1 infection.

This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.

This combination inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection.

At a glance

Generic nametenofovir + abacavir + lopinavir/ritonavir
SponsorHospital Clinic of Barcelona
Drug classAntiretroviral combination therapy (NRTI + PI/boosted)
TargetHIV reverse transcriptase, HIV protease
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Tenofovir and abacavir are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, preventing viral RNA conversion to DNA. Lopinavir/ritonavir is a protease inhibitor combination where ritonavir boosts lopinavir levels by inhibiting its metabolism, allowing lopinavir to block HIV protease and prevent viral maturation. Together, they suppress HIV replication through multiple mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about tenofovir + abacavir + lopinavir/ritonavir

What is tenofovir + abacavir + lopinavir/ritonavir?

tenofovir + abacavir + lopinavir/ritonavir is a Antiretroviral combination therapy (NRTI + PI/boosted) drug developed by Hospital Clinic of Barcelona, indicated for HIV-1 infection.

How does tenofovir + abacavir + lopinavir/ritonavir work?

This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.

What is tenofovir + abacavir + lopinavir/ritonavir used for?

tenofovir + abacavir + lopinavir/ritonavir is indicated for HIV-1 infection.

Who makes tenofovir + abacavir + lopinavir/ritonavir?

tenofovir + abacavir + lopinavir/ritonavir is developed and marketed by Hospital Clinic of Barcelona (see full Hospital Clinic of Barcelona pipeline at /company/hospital-clinic-of-barcelona).

What drug class is tenofovir + abacavir + lopinavir/ritonavir in?

tenofovir + abacavir + lopinavir/ritonavir belongs to the Antiretroviral combination therapy (NRTI + PI/boosted) class. See all Antiretroviral combination therapy (NRTI + PI/boosted) drugs at /class/antiretroviral-combination-therapy-nrti-pi-boosted.

What development phase is tenofovir + abacavir + lopinavir/ritonavir in?

tenofovir + abacavir + lopinavir/ritonavir is FDA-approved (marketed).

What are the side effects of tenofovir + abacavir + lopinavir/ritonavir?

Common side effects of tenofovir + abacavir + lopinavir/ritonavir include Diarrhea, Nausea, Abdominal pain, Headache, Lipid abnormalities (elevated cholesterol/triglycerides), Lactic acidosis.

What does tenofovir + abacavir + lopinavir/ritonavir target?

tenofovir + abacavir + lopinavir/ritonavir targets HIV reverse transcriptase, HIV protease and is a Antiretroviral combination therapy (NRTI + PI/boosted).

Related